Neutral Endopeptidase Inhibitors and Atrial Natriuretic Peptide

Achilihu, Godfrey; Frishman, William H.; Landau, Andre J.

doi:10.1002/j.1552-4604.1991.tb03773.x

Cited by 6 publications

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NEP is widely distributed in the endothelial cells, vascular smooth muscle cells, cardiac myocytes, renal epithelial cells, and fibroblasts (76,77). NEP inhibition results in consistent increases in urine sodium and cGMP excretion (78). This is because renal tubular NEP is a major site of natriuretic peptide metabolism.…”

Section: Metabolismmentioning

confidence: 99%

Natriuretic Peptides and the Dialysis Patient

Suresh

Farrington

2005

Seminars in Dialysis

View full text Add to dashboard Cite

The natriuretic peptide family consists of four structurally similar, but genetically distinct molecules with pronounced cardiovascular and renal actions. They are counterregulatory hormones playing an important role in fluid volume homeostasis. Atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) cause diuresis, natriuresis, and vasodilatation. C-type natriuretic peptide (CNP) has antimitogenic effects and causes vascular smooth muscle relaxation. Dendroaspis natriuretic peptide (DNP) shares many of the actions of ANP and BNP, but its function in humans is not yet fully understood. Natriuretic peptides have been extensively investigated as biochemical markers of the fluid state. Levels are elevated in disease conditions characterized by fluid overload and are closely related to survival in various cardiac disease states. In the dialysis population, BNP correlates significantly with cardiac function, whereas ANP is sensitive to volume changes during dialysis. However, changes in concentration do not predict achievement of euvolemia, and short half-life, combined with complicated assay techniques, make ANP a less than satisfactory tool for assessing hydration. BNP is a superior prognosticator for risk stratification in dialysis patients, and serial estimations will help in the identification of occult cardiac disease.

show abstract

Section: Metabolismmentioning

confidence: 99%

Natriuretic Peptides and the Dialysis Patient

Suresh

Farrington

2005

Seminars in Dialysis

View full text Add to dashboard Cite

show abstract

Diuretic Agents

Cervoni¹,

Chan²

2000

Kirk-Othmer Encyclopedia of Chemical Technology

View full text Add to dashboard Cite

Diuretics are agents that increase urine output or flow. The effects of diuretic agents on electrolyte and water excretion in the kidney for the treatment of edema, congestive heart failure, ascites, and hypertension are reviewed. The structure and function of the kidney in the formation of urine are presented using the functional unit of the kidney, the nephron. The various sites where absorption, secretion, and the passive and active transport of water and electrolytes alter the composition of the glomerular filtrate from Bowman's capsule as it passes through the lumen of the nephron to the collecting ducts on its way to becoming urine are described. Diuretics are classified as low ceiling, high ceiling (loop), and potassium‐sparing diuretics, natriuretic peptides, atrial natriuretic peptides, atrial natriuretic peptide potentiators, osmotic diuretics, carbonic anhydrase inhibitors, methylxanthines, organomercurials, and aquaretics. The pharmacology, mechanisms or site of action in the nephron, and clinical effectiveness are discussed. Included is a discussion of the risk factors and side effects of diuretic agents.

show abstract

Atrial Natriuretic Peptide and Its Potential Role in Pharmacotherapy

Deutsch

Frishman

Sukenik

et al. 1994

The Journal of Clinical Pharma

View full text Add to dashboard Cite

Atrial natriuretic peptide (ANP) is a 28 amino-acid polypeptide secreted into the blood by atrial myocytes after atrial pressure and distension. Although its role in humans is not clear, it can produce a variety of physiologic effects including vasodilatation, natriuresis, and suppression of the renin-angiotensin-aldosterone axis. These actions are potentially useful in a variety of pathologic states such as hypertension and congestive heart failure, and diverse methods to augment the effects of ANP in these states have been devised. The results are exciting and, despite some problems, may lead to the pharmacologic use of enhancement of ANP actions in several clinical disorders.

show abstract

Neutral Endopeptidase Inhibitors and Atrial Natriuretic Peptide

Cited by 6 publications

References 35 publications

Natriuretic Peptides and the Dialysis Patient

Natriuretic Peptides and the Dialysis Patient

Diuretic Agents

Atrial Natriuretic Peptide and Its Potential Role in Pharmacotherapy

Contact Info

Product

Resources

About